Maze Therapeutics (MAZE) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
8 Jun, 2026Opening remarks and agenda
Meeting called to order by the CEO and Chairperson, emphasizing the benefits of a virtual format for broader participation.
General Counsel introduced as Secretary to keep minutes; Board members, CFO, legal counsel, and Inspector of Elections present.
Shareholder proposals
Two proposals presented: election of two Class I Directors for three-year terms and ratification of Ernst & Young LLP as independent auditor for 2026.
Board recommended voting in favor of both proposals.
Q&A with stakeholders
Stockholders allowed to submit one written question each, limited to 10 minutes for Q&A, but no questions were received.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Maze Therapeutics
- Q2 2026 net loss rose to $44.7M; $20M milestone revenue; $494.9M cash and securities.MAZE
Q2 2026 - Lead assets show strong efficacy and safety, with pivotal trials and key data readouts set for 2026–2027.MAZEGoldman Sachs 47th Annual Global Healthcare Conference 2026
- Lead programs advance in kidney and metabolic diseases, with pivotal trials and strong funding.MAZEJefferies Global Healthcare Conference 2026
- Lead programs in AMKD, PKU, and CKD advance with robust data and cash runway into 2029.MAZEInvestor presentation
- Q1 2026 net loss narrowed to $24.2M; strong pipeline and capital raise extend cash runway into 2029.MAZEQ1 2026
- Vote on director elections and auditor ratification at the June 2026 annual meeting.MAZEProxy filing
- Director elections and auditor ratification headline a meeting focused on governance and oversight.MAZEProxy filing
- Lead programs show promising clinical progress in AMKD, PKU, and CKD, with robust financial support.MAZECorporate presentation
- MZE829 reduced proteinuria by 36% in AMKD, showing strong efficacy and safety.MAZEStudy result